Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy UroGen Pharma stock

Learn how to easily invest in UroGen Pharma stock.

UroGen Pharma Ltd is a biotechnology business based in the US. UroGen Pharma shares (URGN) are listed on the NASDAQ and all prices are listed in US Dollars. UroGen Pharma employs 192 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in UroGen Pharma

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – URGN – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

UroGen Pharma stock price (NASDAQ: URGN)

Use our graph to track the performance of URGN stocks over time.

UroGen Pharma shares at a glance

Information last updated 2022-06-25.
Latest market close$8.19
52-week range$4.85 - $19.66
50-day moving average $6.55
200-day moving average $10.21
Wall St. target price$25.00
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-5.05

Buy UroGen Pharma shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 6 of 6
Name Product Asset types Stock trade fee Minimum deposit Signup bonus
Finder Award
Stocks, ETFs, Cryptocurrency
when you sign up and deposit $100
Trade stocks in the app or online with $0 commissions. Not available in NY, NV, MN, or TN.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.
SoFi Invest
Stocks, ETFs, Cryptocurrency
$10 - $100
when you open an account and place a first crypto trade of $50 - $5,000+
A free way to invest in most equities.
Stocks, Options, ETFs, Cryptocurrency
$200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
JPMorgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$125 - $625
when you open and fund an account with $25,000 - $250,000+
Axos Bank Self Directed Investing
when you open an account and deposit at least $1500.
Vanguard Personal Advisor
Stocks, Mutual funds, ETFs
Financial advice powered by relationships, not commissions.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy UroGen Pharma stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

UroGen Pharma price performance over time

Historical closes compared with the close of $8.19 from 2022-06-30

1 week (2022-06-23) 3.80%
1 month (2022-06-01) 57.80%
3 months (2022-04-01) -6.29%
6 months (2021-12-31) -13.88%
1 year (2021-07-01) -47.70%
2 years (2020-07-01) -67.88%
3 years (2019-07-01) 36.44
5 years (2017-06-30) 18.06

UroGen Pharma financials

Revenue TTM $54.1 million
Gross profit TTM $42.9 million
Return on assets TTM -41.87%
Return on equity TTM -381.3%
Profit margin -209.3%
Book value $0.38
Market capitalisation $186.1 million

TTM: trailing 12 months

UroGen Pharma share dividends

We're not expecting UroGen Pharma to pay a dividend over the next 12 months.

UroGen Pharma share price volatility

Over the last 12 months, UroGen Pharma's shares have ranged in value from as little as $4.85 up to $19.66. A popular way to gauge a stock's volatility is its "beta".

URGN.US volatility(beta: 1.42)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while UroGen Pharma's is 1.4188. This would suggest that UroGen Pharma's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

UroGen Pharma overview

UroGen Pharma Ltd. , a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102, which is in Phase III clinical trials for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-301 for the treatment of high-grade non-muscle invasive bladder cancer. The company has a license agreement with Allergan Pharmaceuticals International Limited for developing and commercializing pharmaceutical products that contain RTGel and clostridial toxins; Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and strategic research collaboration with MD Anderson to advance investigational treatment for high-grade bladder cancer.

Frequently asked questions

What percentage of UroGen Pharma is owned by insiders or institutions?
Currently 8.959% of UroGen Pharma shares are held by insiders and 80.685% by institutions.
How many people work for UroGen Pharma?
Latest data suggests 192 work at UroGen Pharma.
When does the fiscal year end for UroGen Pharma?
UroGen Pharma's fiscal year ends in December.
Where is UroGen Pharma based?
UroGen Pharma's address is: 400 Alexander Park, Princeton, NJ, United States, 08540
What is UroGen Pharma's ISIN number?
UroGen Pharma's international securities identification number is: IL0011407140
What is UroGen Pharma's CUSIP number?
UroGen Pharma's Committee on Uniform Securities Identification Procedures number is: M96088105

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site